Breast Biopsy Devices Market By Type (Biopsy Needles, Guidance Systems, Biopsy Tables, Localization Wires, Assay Kits), Procedure (Needle Breast Biopsy, Open Surgical Breast Biopsy, Liquid Breast Biopsy), Technique (Image Guided Biopsy, Liquid Biopsy), & Region for 2024-2031

Published Date: August - 2024 | Publisher: MIR | No of Pages: 320 | Industry: latest updates trending Report | Format: Report available in PDF / Excel Format

View Details Buy Now 2890 Download Sample Ask for Discount Request Customization

Breast Biopsy Devices Market Valuation – 2024-2031

Insurance coverage and government reimbursement policies for breast cancer diagnosis play an important role. Broader insurance coverage for breast biopsies makes the treatment more accessible to a wider patient population. The increasing government initiative and reimbursement policies are driving the growth of market size to surpass USD 2.12 Billion in 2024, to reach a valuation of USD 3.02 Billion by 2031.

The increased preference for minimally invasive techniques over standard surgical biopsies is a major motivator. Newer biopsy devices include smaller needles, shorter recovery times, and less discomfort for patients, making them an appealing option. The growing preference for minimally invasive procedures is enabling the market to grow at a CAGR of 4.50% from 2024 to 2031.

Breast Biopsy Devices MarketDefinition/ Overview

A breast biopsy devices is a specialized medical instrument that extracts a tissue sample from the breast during a biopsy surgery. These devices are classified into numerous varieties based on the type of biopsy being conducted. The most common breast biopsy devices are core biopsy needles, fine needle aspiration needles, vacuum-assisted biopsy needles, stereotactic biopsy devices, and ultrasound probes. Breast biopsy devices need less invasive procedures, allowing doctors to obtain reliable diagnoses, and allowing them to adopt focused treatment strategies quickly. Biopsy technology is continually pushing the boundaries, providing improved accuracy, minimally invasive techniques, and rapid diagnosis.

When it comes to fighting breast cancer, finding it early can make all the difference. Breast biopsy devices are like our brave soldiers on the frontlines of this battle. These specialized tools help doctors collect tissue samples to diagnose breast cancer, so they can create personalized treatment plans for each patient. Several factors are fueling the growth of the breast biopsy device market. First, more people are being diagnosed with breast cancer worldwide. Second, people are becoming more aware of the importance of early detection. And third, biopsy technology is constantly improving. The focus is on making biopsy procedures less invasive, more accurate, faster, and more comfortable for patients. This is creating a booming market for breast biopsy devices, as they offer the potential to improve patient care, tailor treatments, and reach new patients in developing countries.

What's inside a
industry report?

Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.

How the Rising Prevalence of Breast Cancer in Women and Growing Awareness of Breast Cancer is Driving the Growth of Breast Biopsy Devices?

Breast cancer is becoming more common around the world, which is making the market for breast biopsies grow. Most women get diagnosed with breast cancer when they're older. There are also certain factors that can increase the risk, like genes, dense breasts, and a family history of breast or ovarian cancer. In 2022, about 2.3 million women were told they had breast cancer, and sadly, 670,000 of them passed away. Out of 185 countries, breast cancer is the most common cancer among women in 157 of them. The good news is that the death rate from breast cancer has been going down by 2.5% every year. Another thing that's increasing the number of breast cancer cases is the growing number of older people. In 2021, there were 761 million people in the world who were over 65, and that number is expected to keep going up. In Asia, about 4.5 billion people were over 65 in 2020. As people get older, their risk of getting breast cancer goes up, especially after menopause, which is usually around 40 years old.

The growing global awareness of breast cancer is driving up demand for breast cancer biopsy devices. Breast health awareness encompasses public and professional medical education on the dangers and symptoms of breast cancer, as well as the significance of medical evaluation for breast issues. Collaboration with cancer survivors, advocacy organizations, and community groups is critical for the effective design and dissemination of breast health awareness messaging. Breast cancer programs in low- and middle-income countries (LMICs) should adhere to a defined care pathway that takes into account available resources and capacities, allowing for coordinated incremental program development across the care continuum. Mammographic screening has been demonstrated to minimize breast cancer mortality in high-resource countries.

The technological advancement in cancer biopsy widely increasing and is highly adopted by professionals and developed countries. Positron emission tomography (PET) is used to measure the specific organ blood flow. It provides both functional and anatomical information, it analyzes the metastasis via lymph nodes more precisely than the conventional imaging. Computed tomography (CT) is used as a series of X-rays to take images of different angles. It scans quickly and has the potential to decrease motion artifacts, give accurate spatial information, and is used to construct digital radiographs. Magnetic resonance imaging (MRI) the contrast agent which is used in MRI is less likely to cause an allergic reaction compared to the iodine-based contrast agents. In addition, magnetic resonance spectroscopy (MRS) can give biological, physiological, anatomical, and metabolic information.

Also, the image-guided technologies are driving growth in the market. Breast biopsies are becoming more precise and efficient thanks to advances in image-guided technology like ultrasonography and stereotactic guidance systems. These advances allow for more precise targeting of questionable tissue samples, reducing the possibility of problems and the need for additional treatments. Mammotome or Vacora biopsies can be performed using ultrasound instead of a mammography. These techniques are comparable to stereotactic biopsy but include lying on your back with no compression or X-rays.

How the High Cost Associated with the Cancer Biopsy is Limiting the Growth of the Breast Biopsy Devices Market?

Advanced biopsy devices can be costly to purchase and operate. This can reduce accessibility, especially in areas with limited healthcare resources or for patients with limited insurance coverage. Biopsies cost between $307 for a tiny needle biopsy and $3,296 for a sophisticated surgical biopsy, with other biopsies costing $12,353. Mediastinum biopsies cost an average of $10,554. The cost of a vacuum-assisted biopsy is USD 264 per case.

The rise of liquid biopsy techniques, which study cancer cells in circulation, could provide a future challenge in the cancer biopsy device. Although not intended as a direct substitute, these non-invasive diagnostics may evolve into a screening tool, perhaps reducing the urgent need for tissue biopsies in certain situations. Liquid biopsies have the benefit of being less intrusive because they only entail the extraction of blood samples rather than tissue removal. As AI and digital technologies grow more common in biopsy instruments, data security is critical. With the possibility for sensitive patient information to be kept and exchanged online, strong cybersecurity safeguards are required. These safeguards aim to prevent unwanted access and data breaches, protect patient privacy, and ensure the integrity of medical data. As a result, healthcare institutions and device makers must invest in advanced security protocols and continuously upgrade their systems to combat new threats in the digital realm.

In addition, compliance with regulatory standards such as HIPAA (Health Insurance Portability and Accountability Act) is critical for maintaining patient confidentiality and trust in medical practices. By emphasizing data security, healthcare practitioners can confidently use AI and digital technologies to improve diagnostic accuracy and patient care while reducing the dangers of illegal access to sensitive medical information.

Category-Wise Acumens

How the Technological Advancements in the Biopsy Device Market are Driving the Growth of the Biopsy Needles Segment?

The biopsy needles segment is showing substantial growth in the Breast Biopsy Devices Market and is expected to continue its growth throughout the forecast period thanks to the technological advancements and the new product launches that are driving the growth of the biopsy needles segment in the market. The biopsy needle’s thin design allows for minimally invasive operations, which reduces patient discomfort, recuperation time, and complications. This minimally invasive nature also enables outpatient operations, which improves patient convenience. Versatility is another important asset.

Biopsy needles come in a variety of sizes, each designed to collect distinct types of tissue samples based on the location and characteristics of the suspicious area. Core biopsy needles extract bigger tissue cores for a thorough investigation, whereas fine-needle aspiration needles obtain a preliminary diagnosis from a smaller sample. Vacuum-assisted needles provide a compromise, gathering larger samples than ordinary core needles. Furthermore, biopsy needles are often less expensive than surgical biopsy equipment, making the treatment available to a wider spectrum of patients.

Also, many biopsy needles work perfectly with image-guided systems such as ultrasonography and stereotactic methods. This real-time imaging of targeted tissue increases sample collection accuracy and lowers the need for additional biopsies. To summarize, biopsy needles are a critical component of cancer biopsy equipment, offering a safe, effective, and cost-effective method of collecting tissue samples for accurate diagnosis.

How the Minimally Invasive Molecular Monitoring of Liquid Biopsy is Driving the Growth of the Breast Biopsy Devices Market?

The liquid Biopsy segment is significantly leading in the Breast Biopsy Devices Market. Liquid biopsy is an appealing option for cancer monitoring thanks to its low invasiveness. Unlike traditional tissue biopsies, which require intrusive procedures, liquid biopsy collects body fluids, typically peripheral blood, making it less stressful for patients. Liquid biopsy allows for the quantification of various genetic materials released into circulation by tumor cells, such as circulating tumor cells (CTCs), cell-free DNA (cfDNA)/circulating tumor DNA (ctDNA), circulating tumor RNA, extracellular vesicles (EVs), circulating tumor proteins, and tumor-educated platelets (TEPs). This extensive sampling yields a more complete picture of the tumor’s molecular composition.

Liquid biopsy has the advantage of being easier to serially evaluate than standard tissue biopsies. With liquid biopsy, practitioners can perform repeated tests over time with minimum discomfort to the patient, allowing for constant monitoring of disease progression and treatment response. Liquid biopsy, when paired with very sensitive molecular technology and modern bioinformatics techniques, can reveal intra-tumoral heterogeneity (spatial heterogeneity) as well as the molecular evolution of distant metastatic lesions. This is especially useful because standard tissue biopsies may not capture the entire spectrum of tumor cells found in heterogeneous tumors.

Unlike tissue biopsies, which may not accurately reflect the entire tumor, liquid biopsy provides a more comprehensive sampling of genetic elements generated by multiple tumor cells circulating in the bloodstream. This reduces the likelihood of non-representative biopsy specimens and gives a more accurate picture of the tumor’s genetic landscape.

Gain Access to Breast Biopsy Devices Market Report Methodology

Country/Region-wise Acumens

How will the Market Fare in North America?

In the world of breast cancer detection, North America stands out as a leader, and this dominance is only expected to grow in the coming years. Why? Because medical advancements are making breast biopsies more accurate and less painful, which is a win-win for patients. These improvements mean that doctors can get the information they need to diagnose and treat breast cancer more easily. And here's another reasonbreast cancer is on the rise in North America. In the United States alone, over 239,000 women were diagnosed with breast cancer in 2020, and sadly, over 42,000 lost their lives to the disease. But here's the silver liningwith more people aware of breast cancer and the importance of early detection, there's a greater need for accurate and fast diagnostic tools like breast biopsy devices.

Favorable reimbursement conditions in the region have made breast biopsy procedures more accessible to patients. Healthcare regulations and insurance coverage schemes have facilitated the adoption of new diagnostic technology, encouraging both healthcare providers and patients to choose these operations. The new breast density notification rules in the United States have expanded the use of breast biopsy technologies. These regulations oblige healthcare providers to educate people about their breast density and the consequences of cancer detection, resulting in increased proactive screening methods and the use of modern biopsy techniques.

Competitive Landscape

The Breast Biopsy Devices Market is competitive and dynamic, with companies continuously striving to innovate and differentiate their offerings to meet the evolving needs of healthcare providers and patients. Collaboration with healthcare professionals and investment in research and development are key strategies for maintaining competitiveness in this rapidly advancing field.

The organizations are focusing on innovating their product line to serve the vast population in diverse regions. Some of the prominent players operating in the Breast Biopsy Devices Market include

  • Aspen Surgical Products Company
  • Deviceph
  • INRAD
  • Epredia
  • Miltenyi Biotec
  • Vacuumassister®
  • IBreast Imaging Systems, Ltd.
  • iGenomix
  • EndoChoice, Inc.
  • Endosight Corporation

Report Scope

REPORT ATTRIBUTESDETAILS
Study Period

2021-2031

Growth Rate

CAGR of ~4.50% from 2024 to 2031

Base Year for Valuation

2024

Historical Period

2021-2023

Forecast Period

2024-2031

Quantitative Units

Value in USD Billion

Report Coverage

Historical and Forecast Revenue Forecast, Historical and Forecast Volume, Growth Factors, Trends, Competitive Landscape, Key Players, Segmentation Analysis

Segments Covered
  • Type
  • Procedure
  • Technique
Regions Covered
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa
Key Players

Aspen Surgical Products Company, Deviceph, INRAD, Epredia, Miltenyi Biotec, Vacuumassister®, IBreast Imaging Systems, Ltd., iGenomix, EndoChoice, Inc., Endosight Corporation

Customization

Report customization along with purchase available upon request

Breast Biopsy Devices Market, By Category

Type

  • Biopsy Needles
  • Guidance Systems
  • Biopsy Tables
  • Localization Wires
  • Assay Kits

Procedure

  • Needle Breast Biopsy
  • Open Surgical Breast Biopsy
  • Liquid Breast Biopsy

Technique

  • Image Guided Biopsy
  • Liquid Biopsy

Region

  • North America
  • Europe
  • Asia-Pacific
  • South America
  • Middle East & Africa

Research Methodology of Market Research

To know more about the Research Methodology and other aspects of the research study, kindly get in touch with our .

Reasons to Purchase this Report

Understanding the Market We'll dig deep into the market, considering both financial and non-financial aspects, to create different groups of customers. We'll give you the value of the market (in billions of dollars) for each group and smaller groups within them. We'll let you know which part of the market is growing fastest and is expected to be the biggest.Regional Insights We'll break down the market by region, showing how much of the product or service is being used in each area. We'll identify the factors that are shaping the market in different regions.Who's Who in the Market We'll introduce you to the key players in the market, ranking them based on their size. We'll keep you updated on the latest product launches, partnerships, and business moves made by these companies.Company Spotlights We'll give you an insider's view of the major companies in the market, including their strengths, weaknesses, and what they've been up to lately. Market Outlook We'll take a look at the current and future state of the market, highlighting the opportunities, challenges, and trends that will shape its growth.Competitive Forces Using Porter's famous "Five Forces" analysis, we'll help you understand the competitive landscape and how it affects the market. Value Chain We'll show you how the different stages of the market connect to each other and create value for customers.Growth Opportunities We'll identify the areas where the market is expected to grow in the coming years, highlighting the opportunities for businesses. Post-Sales Support Our team will be there for you even after you purchase the report, providing ongoing support for up to 6 months.

Customization of the Report

• In case of any please connect with our sales team, who will ensure that your requirements are met.

Pivotal Questions Answered in the Study

Some of the key players leading in the market include Aspen Surgical Products Company, Deviceph, INRAD, Epredia, Miltenyi Biotec, Vacuumassister, IBreast Imaging Systems, Ltd., iGenomix, EndoChoice, Inc., and Endosight Corporation
Insurance coverage and government reimbursement policies for breast cancer diagnosis play an important role. Broader insurance coverage for breast biopsies makes the treatment more accessible to a wider patient population and is propelling the demand for the adoption of the Breast Biopsy Devices Market.
Advanced biopsy devices can be costly to purchase and operate. This can reduce accessibility, especially in areas with limited healthcare resources or for patients with limited insurance coverage limiting the growth of the Breast Biopsy Devices Market.
The Breast Biopsy Devices Market is estimated to grow at a CAGR of 4.50% during the forecast period.

Related Reports

Table of Content

To get a detailed Table of content/ Table of Figures/ Methodology Please contact our sales person at ( chris@marketinsightsresearch.com )

List Tables Figures

To get a detailed Table of content/ Table of Figures/ Methodology Please contact our sales person at ( chris@marketinsightsresearch.com )

FAQ'S

For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:

sales@marketinsightsresearch.com

Within 24 to 48 hrs.

You can contact Sales team (sales@marketinsightsresearch.com) and they will direct you on email

You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.

Discounts are available.

Hard Copy

Email